GeoVax Labs Inc. reported financial results for the first quarter of 2025, revealing a net loss of $5.4 million, compared to a net loss of $5.9 million in the same period of 2024. The company achieved $1.6 million in revenue from government contracts associated with the BARDA/RRPV Project NextGen award, in contrast to no reported revenues in the first quarter of 2024. Research and development expenses rose to $5.4 million from $4.4 million in the previous year, driven by costs related to the BARDA/RRPV Project NextGen award, as well as the Gedeptin and GEO-MVA programs. GeoVax's general and administrative expenses increased to $1.7 million from $1.5 million, attributed to higher investor relations consulting costs and stock-based compensation. The company held cash balances of $7.4 million as of March 31, 2025, up from $5.5 million at the end of 2024. Significant business developments include the ongoing progress of the COVID-19 vaccine program, with additional data expected in the second quarter of 2025, and the initiation of the clinical evaluation of GEO-MVA in the second half of 2025. Additionally, Gedeptin is advancing into a Phase 2 clinical trial for recurrent head and neck cancer treatment.